Structural Heart Market is expected to reach US$ 22,560.88 million by 2028

Publisher: The Insight Partners

Occluders Segment to Hold Largest Share of Structural Heart Market During 2022–2028

According to our latest study on “Structural Heart Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Procedure, and End User,” the structural heart market was valued at US$ 14,245.55 million in 2022 and is expected to reach US$ 22,560.88 million by 2028; it is estimated to record a CAGR of 8.0% from 2022 to 2028. The report highlights the key factors driving the market and prominent players with their developments in the market. 

Based on product, the global structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. The occluders segment held the largest market share of structural heart market in 2022; however, the annuloplasty rings segment is expected to register the highest CAGR during the forecast period. Occluders are one of the most used structural heart devices for treating congenital heart defects such as atrial septal defects, ventricular septal defects, patent ductus arteriosus, and patent foramen ovale. These devices have a double disc structure made up of nitinol mesh and polyester material. These devices are designed to securely appose the septal wall on each side of the defect, which create a platform for tissue in-growth after implantation.

Global Structural Heart Market, by Country (% Share) 2022

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPHE100001164 Source: The Insight Partners Analysis

Availability of Innovative Structural Heart Services Boosts Global Structural Heart Market

The availability of technologically advanced products and treatment services allows surgeons, physicians, and other healthcare providers to offer superior services to their patients, which helps them maintain the optimum quality of life. The innovations are not limited to healthcare facilities, and they are extended to programs that are being designed for patients to get benefits out of treatment facilities. Heart diseases are complex, and the success of their intervention depends on innovations bringing treatment options that were deemed impossible earlier into reality. The heart disease treatment landscape—from structural inventions to surgical valve therapies—has experienced breakthrough innovations over the past few decades. Companies in the structural heart market offer a broad portfolio of solutions for different heart conditions, including vascular disease, irregular heartbeats, and heart valve diseases. Physicians can now manage arrhythmias by using remote monitoring devices to keep a tab on their patients, thereby treating an array of structural heart conditions.

The Food and Drug Administration (FDA) has approved various therapies that are limited to the selected groups of patients. For instance, Premier Health, one of the providers of innovative structural heart services, offers alcohol septal ablation treatment for hypertrophic cardiomyopathy, which mainly uses catheter-based technology. The balloon valvuloplasty provided by Premier Health is a technique that uses a transcatheter approach for widening up stiff and narrow heart valves and atrial septal defect transcatheter repair, which closes an opening between the heart’s left and right atrium without surgery. CentraCare's Heart & Vascular Center used EchoPixel's True3D and HTG pre-planning software, which provides mixed reality capabilities that allow structural heart teams to interact with a real-time holographic version of the patient's anatomy without physically touching it or exposing it to contrast agents and radiations. In August 2021, the first 3D-printed heart valve of an Indian make was developed in Chennai.

The innovative technologies and techniques of structural heart programs are specifically designed to provide quality care for the best results for patients and fewer complications and shorter recovery times with long-lasting advantages. Therefore, such technologies are likely to attract more patients suffering from structural heart diseases, and thereby benefit from the services which is driving the growth of the structural heart market.

Impact of COVID-19 Pandemic on Global Structural Heart Market

The COVID-19 pandemic had a huge impact on the regions across the globe as it tested the resilience of economies and placed immense pressure on health workers. A socio-economic analysis of the impact of the pandemic by the United Nations Development Programme (UNDP) helped governments of various countries overhaul policies and invest in public health, economic stimulus, and social safety. These measures helped countries recover faster from the adversities caused by the COVID-19 crisis. Governments of various countries ensured the uninterrupted availability of life-supporting medical equipment. The COVID-19 pandemic altered economic conditions and social behaviors in North American countries. Containment measures enacted by the US government to mitigate the spread of SARS-CoV-2 changed the pattern of healthcare service delivery in the country. According to the Department of Emergency Medicine, in many cities across the US, emergency department (ED) visits decreased by ~40% in 2020. According to a study titled “Impact of COVID-19 on Management Strategies for Coronary and Structural Heart Disease Interventions,” in 2022, 77 patients were scheduled for TAVR at a tertiary center in the US, and 28.6% of cases were canceled because of the pandemic. The decisions about the timing of SHD interventions considered the risk of delaying the procedure, exposure to COVID-19, and use of limited hospital resources. In the surgical field, hospitals across the country restricted performing elective surgeries, including surgical aortic valve replacement (SAVR), to conserve ventilators, operating rooms, and intensive care unit beds. The structural heart market had witnessed a shortfall at the beginning of the COVID-19 crisis owing to factors such as disruption in supply chain and demand due to the lockdown announced by the majority of European countries that caused disruptions in manufacturing and supply chain operations. Additionally, appointments have been delayed in many clinics owing to the rising number of cases. However, with the implementation of proper guidelines and protocols to reduce SARS-CoV-2 exposure to patients during their visits, the hospitals have begun to continue their CVD operations and adapt their appointment schedules based on local cases of COVID-19. Therefore, there was a short-term impact of the COVID-19 pandemic on the global structural heart market.

Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc., Edwards Lifesciences Corp, Lepu Medical Technology Beijing Co Ltd, Braile Biomédica Industry, Commerce and Representations Ltd, Aran Biomedical Teoranta, Micro Interventional Devices Inc, and Corcym UK Ltd. are among the leading companies operating in the global structural heart market.

Based on product, the global structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. In 2022, the occluders segment held the largest share of the market; however, the annuloplasty rings segment is expected to register the highest CAGR during the forecast period. Occluders are available in different shapes and sizes, along with different features that help in the precise placement of the occluders during the procedure and reduce the chances of dislodging into one of the heart chambers. In September 2022, Abbott launched its Amplatzer Talisman PFO Occlusion System in Europe to treat people with a patent foramen ovale (PFO)–a hole in the heart that doesn't close following birth. These devices are fully repositionable and recapturable, providing a great advantage to healthcare professionals. Based on procedure, the global structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. In 2022, the heart valve stenosis segment held the largest market share and anticipated to register the highest CAGR during the forecast period. Based on end user, the global structural heart market is segmented into hospitals, ambulatory surgical centers, and cardiac centers. In 2022, the hospitals segment held the largest share of the structural heart market, and the same segment is expected to register the highest CAGR during the forecast period.

Contact Us
Contact Person: Content Team 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com